1030PImpact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Monk, B J, Herzog, T J, Triantos, S, Maul, S, Wang, G, Valero, M J Pontes, McGowan, T, Shalaby, W S, Coleman, R L
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
932P - Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
Tagawa, S., Siefker-Radtke, A., Dosne, A.-G., Zhong, B., Qi, K., Shalaby, W., O’Hagan, A., De Porre, P., Mahadevia, P., Loriot, Y.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
Tagawa, S., Siefker-Radtke, A., Dosne, A.-G., Zhong, B., Qi, K., Shalaby, W., O’Hagan, A., De Porre, P., Mahadevia, P., Loriot, Y.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
932PHyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
Tagawa, S, Siefker-Radtke, A, Dosne, A -G, Zhong, B, Qi, K, Shalaby, W, O’Hagan, A, De Porre, P, Mahadevia, P, Loriot, Y
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article